Company Profile
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Latest News
PINK vs. XLV: How Do These Two Health Care ETFs Match Up?
TMO Q2 Deep Dive: Broad-Based End Market Growth and Strategic Portfolio Moves
Thermo Fisher (TMO) Lands ImmuPharma Kapiglucagon Diabetes Manufacturing Role
Thermo Fisher (TMO) Climbs 8.7% on Solid Earnings, Price Target Upgrades
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Website | https://www.thermofisher.com |
| Audit Risk | 2 |
| Board Risk | 7 |
| Overall Risk | 9 |
| Market Cap | 211.18B |
| Trailing P/E | 30.58 |
| Forward P/E | 20.7 |
| Dividend Rate | 1.88 |
| Dividend Yield | 0.33% |
| Trailing Annual Div. Rate | 0.86 |
| Trailing Annual Div. Yield | 0.15% |
| Trailing EPS | 18.58 |
| Forward EPS | 27.45 |
| Book Value | 139.75 |
| Price-to-Book | 4.07 |
| Enterprise-to-Revenue | 5.38 |
| Enterprise-to-EBITDA | 21.25 |
| Short Ratio | 2.52 |
| Ex-Dividend Date | 09/15/2026 |
| Dividend Date | 10/15/2026 |
| Earnings Date | 10/21/2026 |
| Earnings Call Date | 07/23/2026 |
| Earnings Average | 6.4 |
| Earnings Low | 6.32 |
| Earnings High | 6.56 |
| Revenue Average | 11.95B |
| Revenue Low | 11.82B |
| Revenue High | 12.05B |